SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2021
Commission File Number: 001-40106
4D pharma plc
(Translation of Registrant’s name into English)
5th Floor, 9 Bond Court
Tel: +44 (0) 113 895 013
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Announcement of Annual Report and Annual General Meeting
On April 15, 2021, 4D pharma plc (the “Company”) issued a press release to announce that the Annual Report for the year ended December 31, 2020 (the “Annual Report”) and the notice of the Company’s Annual General Meeting (“Notice of AGM”) have been posted to shareholders. The AGM will be held on Monday, May 24, 2021 at 10:00 am (British Summer Time) at the Company’s offices at 9 Bond Court, Leeds LS1 2JZ. Electronic copies of both the Annual Report and Notice of AGM can be found on the Company’s website at www.4dpharmaplc.com.
A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|4D pharma plc|
|Date: April 16, 2021||/s/ Duncan Peyton|
|Chief Executive Officer|
INDEX TO EXHIBITS
|99.1||Press Release, dated April 15, 2021.|
4D pharma PLC
4D pharma plc
(the “Company” or “4D”)
Annual Report and Notice of AGM
Leeds, UK, April 15, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that the Annual Report and Accounts for the year to 31 December 2020 (the “Annual Report”) and the notice of the Company’s Annual General Meeting (“Notice of AGM”) have been posted to shareholders.
Electronic copies of both the Annual Report and the Notice of AGM are now available on the Company’s website, www.4dpharmaplc.com.
The AGM will be held on Monday 24 May 2021 at 10:00 a.m. (British Summer Time) at the Company’s offices, 9 Bond Court, Leeds LS1 2JZ.
About 4D pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
4D pharma’s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson’s disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
4D pharma PLC
Investor Relations: firstname.lastname@example.org
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
Philip Davies / Iqra Amin / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200
Julie Seidel Julie.email@example.com
Image Box Communications +44 (0)20 8943 4685
Neil Hunter / Michelle Boxall
firstname.lastname@example.org / email@example.com